← Back to signals
REGN
STRONG BUYRegeneron Pharmaceuticals Inc.
Health Care
0.57
PEGY ratio
Rank #49
Why This Matters
This stock appears significantly undervalued relative to its growth and dividend yield. Strong projected growth of 31.2% annually over 5 years. Pays a 0.6% dividend yield.
REGN is trading at 14.7x earnings against 25.0% capped growth (actual 31.2%) + 0.6% yield, giving a PEGY of 0.57. The math suggests the stock is significantly undervalued relative to its growth and income profile.
~ Growth estimate uses historical CAGR (forward estimates unavailable)
- • Growth rate derived from historical CAGR — limited analyst coverage.
- • Growth rate capped at 25% for PEGY calculation (actual: 31.2%). Per Peter Lynch methodology, growth above 25% is rarely sustainable over 5 years.
Scan date: 2026-06-02
Valuation
14.7x
P/E Ratio
Growth
31.2%
5yr EPS
Income
0.6%
Div Yield
PEGY Components
PEGY Score0.57
Denominator25.6%
EPS (TTM)$40.97
Market Data
Price$600.66
ExchangeNASDAQ
S&P 500Nasdaq 100
What Changed
PEGY Score
0.61→0.57(-0.04)
Rank
#64→#49(+15 positions)
vs 7 days ago
Portfolio Context
Founder does not hold this stock.
Not in your portfolio.
Sector: Health Care
PEGY History — 90 days
Data: Yahoo Finance • Updated nightly 11 PM ET • For informational purposes only